http://api.archives-ouvertes.fr/search/?fq=halId_s:hal-02616951&fl=title_s,en_title_s,docid,label_s,en_label_s,docType_s,authIdHal_s,halId_s,structId_i,uri_s,keyword_s,en_keyword_s,authLastNameFirstName_s,journalTitle_s,abstract_s,en_abstract_s,producedDate_tdate,producedDateY_i,language_s,fileMain_s&sort=publicationDate_s+desc
authors
- Dardaud Laure-Marie
- Bris Céline
- Desquiret-Dumas Valérie
- Boisselier Blandine
- Tabouret Emeline
- Mokhtari Karima
- Figarella-Branger Dominique
- Rousseau Audrey
- Procaccio Vincent
keywords
- Glioblastoma
- Mitochondrial genome
- MtDNA copy number
- Prognosis and survival
- Young adults
document type
ART
abstract
Glioblastoma (GB) is the most common and most aggressive form of diffuse glioma, with a median overall survival of 15 months after standard of care.1 Young GB patients (<40 years old) may carry isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations or, in rare instances, harbor H3F3A or HIST1H3B mutations. Other cases are wild-type for those genes and harbor gain of chromosome (chr) 7, loss of chr 10, and epidermal growth factor receptor (EGFR) amplification (amp). IDH1/2 mutations are associated with longer survival (24 mo), whereas...
more information